As investors welcome early efficacy signal, Rubius sees platform validation in results

Rubius believes an early readout from its lead program in solid tumors represents a validating event for its RED platform, but after seeing a 13% overall response rate in a clinical study, the company is still searching for the right dose and patient population for the next stage of the engineered red blood cell therapy’s development.

Shares of Rubius Therapeutics Inc. (NASDAQ:RUBY) fluctuated on the news Monday as investors reacted to safety and efficacy data in its announcement. The market was also assessing how the results reflect on Rubius’ other programs, including one that has reached the clinic...